Replimune (REPL) Total Non-Current Liabilities (2018 - 2026)

Replimune (REPL) reported Total Non-Current Liabilities of $165.8 million for Q1 2026, up 23.21% on a YoY basis from $134.5 million in Q1 2025, and up 35.48% sequentially from $122.4 million in Q4 2025.

Replimune (REPL) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends

Replimune (REPL) has 7 years of Total Non-Current Liabilities data on file, last reported at $165.8 million in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities rose 23.21% year-over-year to $165.8 million; the trailing twelve-month figure through Mar 2026 stood at $165.8 million (up 23.21% YoY), and the FY2026 full-year result was $165.8 million, up 23.21% from the prior year.
  • Total Non-Current Liabilities grew to $165.8 million in Q1 2026, from $122.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $165.8 million in Q1 2026 to a low of $50.0 million in Q1 2022.
  • A 5-year average of $112.4 million and a median of $114.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities surged 81.79% in 2023 and gained 1.98% in 2025, its largest moves.
  • Tracing REPL's Total Non-Current Liabilities over 5 years: stood at $50.0 million in 2022, then surged by 121.36% to $110.6 million in 2023, then climbed by 8.49% to $120.0 million in 2024, then increased by 1.98% to $122.4 million in 2025, then surged by 35.48% to $165.8 million in 2026.
  • Business Quant data shows REPL's Total Non-Current Liabilities at $165.8 million in Q1 2026, $122.4 million in Q4 2025, and $125.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Replimune 970.73 Mn 970.73 Mn - 165.77 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 165.77 Mn
Dec 31, 2025 122.36 Mn
Sep 30, 2025 125.17 Mn
Jun 30, 2025 131.85 Mn
Mar 31, 2025 134.54 Mn
Dec 31, 2024 119.99 Mn
Sep 30, 2024 115.96 Mn
Jun 30, 2024 107.73 Mn
Mar 31, 2024 112.43 Mn
Dec 31, 2023 110.60 Mn
Sep 30, 2023 96.75 Mn
Jun 30, 2023 89.28 Mn
Mar 31, 2023 90.83 Mn
Mar 31, 2022 49.96 Mn
Mar 31, 2019 16.47 Mn
Dec 31, 2018 8.95 Mn
Sep 30, 2018 3.78 Mn
Jun 30, 2018 4.54 Mn
Mar 31, 2018 5.22 Mn